Volume 88, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Cutaneous leishmaniasis is clinically widespread but lacks treatments that are effective and well tolerated. Because all present drugs have been grandfathered into clinical use, there are no examples of a pre-clinical product evaluation scheme that lead to new candidates for formal development. To provide oral agents for development targeting cutaneous leishmaniasis, we have implemented a discovery scheme that incorporates and testing of efficacy, toxicity, and pharmacokinetics/metabolism. Particular emphasis is placed on testing, progression from higher-throughput models to those with most clinical relevance, and efficient use of resources.


Article metrics loading...

Loading full text...

Full text loading...



  1. Desjeux P, , 2001. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 95: 239243.[Crossref]
  2. World Health Organization, 2010. Control of the leishmaniases. World Health Organ Tech Rep Ser 949: 1186.
  3. Gonzalez U, Pinart M, Reveiz L, Rengifo-Pardo M, Tweed J, Macaya A, Alvar J, , 2010. Designing and reporting clinical trials on treatments for cutaneous leishmaniasis. Clin Infect Dis 51: 409419.[Crossref]
  4. Sharlow ER, Grögl M, Johnson J, Lazo JS, , 2010. Anti-leishmanial drug discovery: rising to the challenges of a highly neglected disease. Mol Interv 10: 7275.[Crossref]
  5. Ben Salah A, Buffet PA, Morizot G, Ben Massoud N, Zâatour A, Ben Alaya N, Haj Hamida NB, El Ahmadi Z, Downs MT, Smith PL, Dellagi K, Grögl M, , 2009. WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a Phase 2, randomized, double blind, placebo controlled study. PLoS Negl Trop Dis 3: e432.[Crossref]
  6. Sharlow ER, Close D, Shun T, Leimgruber S, Reed R, Mustata G, Wipf P, Johnson J, O'Neil M, Grögl M, Magill AJ, Lazo JS, , 2009. Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen. PLoS Negl Trop Dis 3: e540.[Crossref]
  7. Sharlow ER, Leimgruber S, Yellow-Duke A, Barrett R, Wang QJ, Lazo JS, , 2008. Development, validation and implementation of immobilized metal affinity for phosphochemicals (IMAP)-based high-throughput screening assays for low-molecular-weight compound libraries. Nat Protoc 3: 13501363.[Crossref]
  8. De Muylder G, Ang KK, Chen S, Arkin MR, Engel JC, McKerrow JH, , 2011. A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit. PLoS Negl Trop Dis 5: e1253.[Crossref]
  9. Zhu X, Pandharkar T, Werbovetz K, , 2012. Identification of new antileishmanial leads from hits obtained by high-throughput screening. Antimicrob Agents Chemother 56: 11821189.[Crossref]
  10. Sakthianandeswaren A, Foote SJ, Handman E, , 2009. The role of host genetics in leishmaniasis. Trends Parasitol 25: 383391.[Crossref]
  11. Hanson WL, Chapman WL, Waits VL, Lovelace JK, , 1991. Development of Leishmania (Vianna) panamensis lesions and relationship of numbers of amastigotes to lesion areas on antimony-treated and untreated hamsters. J Parasitol 77: 780783.[Crossref]
  12. Mortelmans K, Zeiger E, , 2000. The Ames Salmonella/M microsome mutagenicity assay. Mutat Res 455: 2960.[Crossref]
  13. Fenech M, , 2000. The in vitro micronucleus technique. Mutat Res 455: 8195.[Crossref]
  14. Sanguinetti M, Mitcheson J, , 2005. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci 26: 119124.[Crossref]
  15. Serrano-Martín X, Payares G, De Lucca M, Martinez JC, Mendoza-León A, Benaim G, , 2009. Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis. Antimicrob Agents Chemother 53: 51085113.[Crossref]
  16. Silva-Almeida M, Carvalho LO, Abreu-Silva AL, d'Escoffier LN, Calabrese KS, , 2010. Leishmania (Leishmania) amazonensis infection: muscular involvement in BALB/c and C3H.HeN mice. Exp Parasitol 124: 315318.[Crossref]
  17. Castilho TM, Goldsmith-Pestana K, Lozano C, Valderrama L, Saravia NG, McMahon-Pratt D, , 2010. Murine model of chronic L. (Viannia) panamensis infection: role of IL-13 in disease. Eur J Immunol 40: 28162829.[Crossref]
  18. Tonui W, Titus RG, , 2007. Cross-protection against Leishmania donovani but not L. braziliensis caused by vaccination with L. major soluble promastigote exogenous antigens in BALB/C mice. Am J Trop Med Hyg 76: 579584.
  19. Morais-Teixeira E, Carvalho AS, Costa J, Duarte SL, Mendonça JS, Boechat N, Rabello A, , 2008. In vitro and in vivo activity of meglumine antimoniate produced at Farmanguinhos-Fiocruz, Brazil, against Leishmania (Leishmania) amazonensis, L. (L.) chagasi and L. (Viannia) braziliensis . Mem Inst Oswaldo Cruz 103: 358362.[Crossref]

Data & Media loading...

  • Received : 30 Dec 2011
  • Accepted : 03 Nov 2012

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error